Interpretation of Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia(2024)
-
摘要: 文章主要对《中华血液学杂志》发表的《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识(2024年版)》进行解读。作为B细胞急性淋巴细胞白血病(B-cell acute lymphoblastic leukemia，B-ALL)领域目前唯一上市的双特异性T细胞衔接器分子，贝林妥欧单抗在多个临床研究中被证明能为B-ALL患者带来良好的生存获益和可管理的安全性。本解读深入分析贝林妥欧单抗的关键临床研究数据，立足当下，展望未来，探讨了B-ALL领域治疗格局改变的方向。
-
关键词:
- 双特异性T细胞衔接器 /
- 免疫治疗 /
- 急性淋巴细胞白血病
Abstract: To interpret the Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia(2024), which was published in the Chinese Journal of Hematology. As the first and only approved bispecific T cell engager molecule, blinatumomab has been proven to provide significant survival benefits and manageable safety profiles in numerous clinical trials. This interpretation focuses on analyzing key clinical trial data for blinatumomab, discussing current findings, and exploring future directions for the evolving treatment landscape in B-cell acute lymphoblastic leukemia.-
Key words:
- bispecific T cell engager /
- immunotherapy /
- acute lymphoblastic leukemia
-
-
[1] Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults[J]. N Engl J Med, 2024, 391(4): 320-333. doi: 10.1056/NEJMoa2312948
[2] Jabbour E. Blinatumomab alternating with low-intensity chemotherapy treatment for older adults with newly diagnosed Philadelphia(Ph)-negative B-cell precursor acute lymphoblastic leukemia(BCP-ALL)is well tolerated and efficacious: safety run-in results for the phase 3 randomized controlled Golden Gate Study[C]. Poster presented at: 64th American Society of Hematology(ASH)Annual Meeting; December 10-13, 2022;New Orleans, LA, and virtual. Poster 2732.
[3] Jabbour E, Aldoss I, Fleming S, et al. Blinatumomab alternating with low-intensity chemotherapy(LIC)in older adults with newly diagnosed B-cell acute lymphoblastic leukemia(ALL): safety run-in follow-up for the phase 3 Golden Gate Study[C]. EHA Library, 2024, 420480;P416.
[4] Gökbuget N, Schwartz S, Faul C, et al. Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR∷ABL Negative B-Precursor Adult Lymphoblastic Leukemia(ALL): Preliminary Results of the GMALL Bold Trial[J]. Blood, 2023, 142(Supplement 1): 964-964. doi: 10.1182/blood-2023-180472
[5] Wieduwilt M, Yin J, Kour O, et al. Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: ALLIANCE A041703[C]. EHA, 2023, S117.
[6] Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms[J]. Leukemia, 2021, 35(11): 3044-3058. doi: 10.1038/s41375-021-01277-3
[7] Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia[J]. JAMA Oncol, 2018, 4(10): 1413-1420. doi: 10.1001/jamaoncol.2018.1915
[8] Jabbour E, Haddad FG, Short NJ, et al. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review[J]. JAMA Oncol, 2022, 8(9): 1340-1348. doi: 10.1001/jamaoncol.2022.2398
[9] Short N, Jabbour E, Jain N, et al. A chemotherapy-free combination of ponatinib and blinatumomab for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Subgroup analysis from a Phase Ⅱ Study[C]. EHA Library, 2023, S118.
[10] Haddad FG, Jabbour E, Short NJ, et al. Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase Ⅱ Trial[J]. Blood, 2023, 142: 2827-2829. doi: 10.1182/blood-2023-188064
[11] Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial[J]. Blood, 2018, 132(4): 393-404. doi: 10.1182/blood-2016-09-739086
[12] Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2017, 376(9): 836-847. doi: 10.1056/NEJMoa1609783
[13] Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2019, 60(9): 2214-2222. doi: 10.1080/10428194.2019.1576872
[14] Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2018, 131(14): 1522-1531. doi: 10.1182/blood-2017-08-798322
[15] Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial[J]. JAMA, 2021, 325(9): 833-842. doi: 10.1001/jama.2021.0669
[16] Badar T, Szabo A, Litzow M, et al. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data[J]. Bone Marrow Transplant, 2021, 56(8): 1998-2004. doi: 10.1038/s41409-021-01279-w
[17] Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL[J]. J Clin Oncol, 2022, 40(9): 932-944. doi: 10.1200/JCO.21.01405
[18] Gupta VK, Roloff GW, Muffly LS, et al. Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel(Brexu-cel)in Adult Patients with Relapsed or Refractory(r/r)B-Cell Acute Lymphoblastic Leukemia(B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL(ROCCA)[J]. 2023, Blood, 142(supplement_1): 2119.
[19] Schultz LM, Baggott C, Prabhu S, et al. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report[J]. J Clin Oncol, 2022, 40(9): 945-955. doi: 10.1200/JCO.20.03585
[20] Marschollek P, Liszka K, Mielcarek-Siedziuk M, et al. Blinatumomab Prior to CAR-T Cell Therapy-A Treatment Option Worth Consideration for High Disease Burden[J]. Biomedicines, 2022, 10(11): 2915. doi: 10.3390/biomedicines10112915
[21] Bonifacio M, Papayannidis C, Lussana F, et al. Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia[J]. Front Oncol, 2022, 11: 804714. doi: 10.3389/fonc.2021.804714
[22] Stein AS, Larson RA, Schuh AC, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia[J]. Blood Adv, 2018, 2(13): 1522-1531. doi: 10.1182/bloodadvances.2018019034
[23] Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study[J]. Blood Cancer J, 2020, 10(7): 77. doi: 10.1038/s41408-020-00342-x
-
计量
- 文章访问数: 259
- 施引文献: 0
下载: